HCW Biologics (HCWB) Depreciation & Amortization (CF) (2020 - 2025)
HCW Biologics' (HCWB) quarterly Depreciation & Amortization (CF) came in at $419010.0 in Q1 2025, up 72.08% YoY from $243501.0 in Q1 2024, and down 38.61% on a QoQ basis from $682507.0 in Q4 2024.
HCW Biologics (HCWB) Depreciation & Amortization (CF) (2020 - 2025) Analysis & Trends
HCW Biologics (HCWB) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $419010.0 in Q1 2025.
- Quarterly Depreciation & Amortization (CF) rose 72.08% year-over-year to $419010.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $419010.0 (down 64.62% YoY) and the FY2025 annual result came in at $507021.0, down 57.19% from the prior year.
- Depreciation & Amortization (CF) retreated to $419010.0 in Q1 2025, from $682507.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $682507.0 in Q4 2024 to a low of $107463.0 in Q4 2021.
- A 5-year average of $235296.2 and a median of $164333.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 148.59% in 2024, down 54.3% in 2024.
- Tracing HCWB's Depreciation & Amortization (CF) over 5 years: stood at $107463.0 in 2021, then surged by 143.02% to $261158.0 in 2022, then increased by 5.13% to $274550.0 in 2023, then soared by 148.59% to $682507.0 in 2024, then tumbled by 38.61% to $419010.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $419010.0 (Q1 2025), $682507.0 (Q4 2024), and $128449.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | HCW Biologics | 2.86 Mn | 2.11 Mn | -93,887.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 419,010.00 |
| Mar 31, 2025 | 419,010.00 |
| Dec 31, 2024 | 682,507.00 |
| Dec 31, 2024 | 682,507.00 |
| Sep 30, 2024 | 128,449.00 |
| Sep 30, 2024 | 128,449.00 |
| Jun 30, 2024 | 129,932.00 |
| Jun 30, 2024 | 129,932.00 |
| Mar 31, 2024 | 243,501.00 |
| Mar 31, 2024 | 243,501.00 |
| Dec 31, 2023 | 274,550.00 |
| Dec 31, 2023 | 274,550.00 |
| Sep 30, 2023 | 277,454.00 |
| Sep 30, 2023 | 277,454.00 |
| Jun 30, 2023 | 284,333.00 |
| Jun 30, 2023 | 284,333.00 |
| Mar 31, 2023 | 298,847.00 |
| Mar 31, 2023 | 298,847.00 |
| Dec 31, 2022 | 261,158.00 |
| Dec 31, 2022 | 261,158.00 |